  - $133.07
5.35 (4.19%) - 05/19/17
- BERN
05/19/17
INITIATIONBERN
Outperform Nvidia initiated at Bernstein As noted earlier, Bernstein started coverage of Nvidia with a $165 price target and an Outperform rating. The analyst thinks that the stock can rise further, driven by a large datacenter total available market, significant automotive growth, and sustainable gaming growth. - 05/18/17
- BERN
05/18/17
INITIATIONTarget $165
BERN
Outperform Nvidia initiated with an Outperform at Bernstein Bernstein initiated Nvidia with an Outperform and a $165 price target. - 05/15/17
- GSCO
05/15/17
NO CHANGETarget $165
GSCO
Conviction Buy Nvidia price target raised to $165 from $130 at Goldman Sachs Goldman Sachs analyst Toshiya Hari said hte market continues to under-appreciate Nvidia's Datacenter long-term growth opportunity. Hari was surprised by last week's launch of Volta and the associated improvement in performance and sees meaningful upside to Street estimates for FY18/19. The analyst remains positive on Nvidia's positioning in AI/ML inference market and 2020 TAM forecasts provided by the company and reiterates his Coviction Buy rating. - 05/12/17
- RBCM
Nvidia price target raised to $150 from $138 at RBC Capital After attending Nvidia's Analyst Day, RBC Capital analyst Mitch Steves raised his price target on Nvidia. The analyst thinks that the company's high margin data center revenue should grow by triple digit percentage levels and he estimates that its artificial intelligence revenue is increasing "more than 200%." He keeps an Outperform rating on the stock. - $171.93
0.19 (0.11%) - 05/18/17
- CANT
05/18/17
INITIATIONTarget $194
CANT
Overweight Thermo Fisher initiated with an Overweight at Cantor Cantor Fitzgerald analyst Bryan Brokmeier initiated Thermo Fisher with an Overweight rating, as he sees significant opportunity for organic growth and for M&A. He set a $194 price target on Thermo Fisher, which he calls a "key beneficiary" of continued strength in biopharma. - 05/16/17
- JEFF
05/16/17
DOWNGRADETarget $35
JEFF
Hold Patheon downgraded to Hold from Buy at Jefferies Jefferies analyst David Windley downgraded Patheon (PTHN) to Hold saying he sees little risk to the Thermo Fisher (TMO) takeover deal ultimately closing by year-end 2017. The believes the offer fairly values Patheon. The analyst raised his price target for the shares to $35 from $32. - 05/15/17
- PIPR
05/15/17
DOWNGRADETarget $35
PIPR
Neutral Patheon downgraded to Neutral from Overweight at Piper Jaffray Piper Jaffray analyst Sean Wieland downgraded Patheon (PTHN) to Neutral from Overweight and raised his price target to $35 from $33 to reflect the company's agreement to be acquired by Thermo Fisher (TMO). In his downgrade note, Wieland added that Catalent (CTLT) is comparable to Patheon and would trade at $36 if the same valuation as used in Thermo Fisher's deal is applied. - 05/09/17
- BOFA
05/09/17
NO CHANGETarget $200
BOFA
Buy Thermo Fisher added to US 1 List at BofA/Merrill BofA/Merrill analyst Derik de Bruin added Thermo Fisher to the US 1 List following the better-than-expected Q1 report and increased its price target to $200 from $190. The analyst said Thermo is one of the best positioned life science tools companies with strong execution, improving comps ahead, and a potential end market rebound. - $151.90
1.12 (0.74%) - 05/16/17
- MSCO
05/16/17
NO CHANGETarget $212
MSCO
Overweight IBM at attractive entry point ahead of mainframe cycle, says Morgan Stanley Morgan Stanley analyst Katy Huberty attributes recent weakness in shares of IBM (IBM) to the combination of the news that Warren Buffett's Berkshire Hathaway (BRK.A) cut its stake by a third and the company's weak Q1 gross margin trends. However, growth accelerates and margins expand historically for IBM around a mainframe cycle, making the pullback an attractive entry point, according to Huberty. The analyst, who sees a number of the gross margin pressures that have recently plagued IBM abating in the second half of 2017, has a $212 price target on Big Blue's shares. - 05/08/17
- BERN
IBM shouldnt be bought on weakness, says Bernstein Bernstein analyst A.M. (Toni) Sacconaghi, Jr.does not recommend buying IBM on weakness. The analyst says that the success of the company's turnaround efforts is "uncertain," while the stock is still expensive. The analyst keeps a Market Perform rating. - 04/20/17
- ARGS
IBM a value play that's 'becoming a growth story,' says Argus After IBM reported lower than expected revenue and what Argus analyst Jim Kelleher sees as "weak" gross margins, the analyst says that the stock remains a value play, given its decline from its peak prices above $215. However, the analyst thinks that the company is on the path to becoming a unique cloud and cognitive paltform" and is transitioning to "a growth story." The analyst is upbeat on the company's Watson solution and keeps a $192 price target and a Buy rating on the stock. - 05/18/17
- PACS
05/18/17
INITIATIONPACS
Sector Weight IBM initiated with a Sector Weight at Pacific Crest - $16.90
0.2 (1.20%) - 02/23/17
- SBSH
02/23/17
NO CHANGETarget $17
SBSH
Buy Citi says buy Conduent despite 'real mess' of a quarter Citi analyst Jim Suva says Conduent is not "structurally flawed" following its "real mess" of a quarter. Much of the company's issues will be cleaned up over the next year as unprofitable contracts come off the books and charges end, Suva tells investors. He recommends buying the shares with a Buy rating and $17 price target. - 01/10/17
- GSCO
01/10/17
UPGRADETarget $8.5
GSCO
Buy Xerox upgraded to Buy from Neutral at Goldman Goldman Sachs analyst Matthew Cabral upgraded Xerox (XRX) to Buy saying the spin-off of the company's Business Process Outsourcing businesses into Conduent (CNDT) is a "major catalyst." The move should produce greater than $1.5B in savings through 2018 and allow for targeted investments in "pockets of growth," Cabral tells investors in a research note. He lowered his price target for Xerox to $8.50 from $10.50. - 05/19/17
- COWN
05/19/17
INITIATIONTarget $18
COWN
Market Perform Conduent initiated with a Market Perform at Cowen Cowen analyst Bryan Bergin initiated Conduent with a Market Perform and an $18 price target saying topline visibility is a key unknown and prefers to wait for evidence on execution. - 01/26/17
- SBSH
01/26/17
INITIATIONTarget $17
SBSH
Buy Conduent initiated with a Buy at Citi Citi analyst Jim Suva started Conduent (CDNT) with a Buy rating and $17 price target. The analyst expects the Xerox (XRX) spinoff to unlock value through cost reductions and an improved focus. He also raised his price target for Xerox shares to $9 from $7.90 and keeps a Buy rating on the name. SBPH Spring Bank Pharmaceuticals - $11.81
-0.19 (-1.58%) - 08/19/16
- WBLR
08/19/16
INITIATIONTarget $26
WBLR
Outperform Spring Bank Pharmaceuticals initiated with an Outperform at William Blair William Blair analyst Y. Katherine Xu started Spring Bank Pharmaceuticals with an Outperform rating and $26 price target. - 03/03/17
- WBLR
HBV space to consolidate over next five years, says William Blair William Blair analyst Y. Katherine Xu sees curing chronic hepatitis B virus infections as "the next frontier" after the success of hepatitis C treatments and believes the market for an HBV cure could be "similar in size to that of HCV," or $200B in cumulative global sales over a span of two decades. She expects consolidation of the HBV market over the next five years, much like what happened with the HCV market. Xu sees Spring Bank Pharmaceuticals (SBPH) and Arbutus (ABUS) as having the strongest data catalysts in 2017, followed by Assembly Biosciences (ASMB) and Arrowhead (ARWR). She has Outperform ratings on the first three stocks and a Market Perform rating on Arrowhead. - 05/02/17
- CHDN
05/02/17
INITIATIONTarget $16.5
CHDN
Buy Spring Bank Pharmaceuticals initiated with a Buy at Chardan Chardan analyst Madhu Kumar initiated Spring Bank Pharmaceuticals with a Buy and a $16.50 price target. - 05/19/17
- JMPS
05/19/17
INITIATIONJMPS
Outperform Spring Bank Pharmaceuticals initiated with an Outperform at JMP Securities JMP Securities analyst Liisa Bayko started coverage of Spring Bank with a $20 price target and an Outperform rating. She says that Spring Bank's SB9 9200 drug could become "a backbone of HBV therapy," creating a multibillion dollar revenue stream for the company. |